Clinical Trial Update: Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating genetically engineered MUC1-activated T-cells for treating recurrent or refractory multiple myeloma, sponsored by Mayo Clinic;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• MUC1-Activated T-Cells

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING